Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Multiple electrolyte abnormalities after pamidronate administration

M Elisaf1, R Kalaitzidis, K C Siamopoulos

  • 1Department of Internal Medicine, University of Ioannina Medical School, Greece.

Nephron
|July 25, 1998
PubMed
Summary

Pamidronate effectively treats hypercalcemia but can cause electrolyte imbalances. This case highlights significant, temporary hypophosphatemia and hypomagnesemia following pamidronate treatment in a multiple myeloma patient.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Executive summary of the Hellenic Atherosclerosis Society guidelines for the diagnosis and treatment of dyslipidemias - 2023.

Atherosclerosis plus·2024
Same author

Protection against stroke with glucagon-like peptide 1 receptor agonists: a systematic review and meta-analysis.

European journal of neurology·2019
Same author

Effects of evolving lipid-lowering drugs on carbohydrate metabolism.

Diabetes research and clinical practice·2017
Same author

PCSK9 in chronic kidney disease.

International urology and nephrology·2017
Same author

Dipeptidyl peptidase-4 inhibitors and protection against stroke: A systematic review and meta-analysis.

Diabetes & metabolism·2016
Same author

Renoprotective Effects of SGLT2 Inhibitors: Beyond Glucose Reabsorption Inhibition.

Current vascular pharmacology·2016

Area of Science:

  • Oncology
  • Nephrology
  • Endocrinology

Background:

  • Pamidronate is a bisphosphonate used to manage tumor-associated hypercalcemia.
  • Transient electrolyte abnormalities are known potential side effects of pamidronate administration.

Observation:

  • A patient with multiple myeloma and severe hypercalcemia received a single 90 mg dose of pamidronate.
  • The patient experienced significant, albeit transient, electrolyte disturbances post-administration.

Findings:

  • The primary electrolyte disturbances observed were hypophosphatemia and hypomagnesemia.
  • These electrolyte abnormalities were directly linked to the pamidronate treatment.

Implications:

  • Understanding these pathophysiological mechanisms is crucial for managing pamidronate therapy.

Related Experiment Videos

  • Monitoring electrolyte levels is recommended during pamidronate treatment for hypercalcemia.